Abiomed Impella Devices Support 37,673 Patients, Enough to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Abiomed Impella Devices Support 37,673 Patients, Enough to Fill Historic Fenway Park

DANVERS, Mass., April 12, 2016 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq: ABMD ), a leading provider of breakthrough heart support technologies, announced today that it has supported 37,673 patients in the U.S. with its Impella® line of heart pumps, enough individuals to fill every seat in Fenway Park.

The 37,673 rd  patient supported with the Impella device was treated at Montefiore Medical Center in New York. “The Impella device enables our hospital to offer percutaneous treatment options for high risk patients with heart failure who cannot undergo surgery,” said Robert T. Pyo, M.D., Associate Director, Cardiac Catheterization Laboratory, who performed the procedure with the Impella heart pump.  “With this device, we are able to safely perform complex coronary interventions in very sick patients who cannot be managed effectively with medical therapy alone.”

“Abiomed has built the field of heart recovery. Our culture is dedicated to our customers and patients and our mission focuses on recovering hearts and saving lives. With our recent FDA approvals, Abiomed will be able to treat more patients and bring more jobs to Massachusetts,” said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed.

Abiomed, founded in 1981 in Danvers, Massachusetts, has approximately 800 employees worldwide, and produces Impella, a line of the world’s smallest heart pumps that can be placed minimally invasively in a hospital catheterization lab, avoiding the necessity of heart surgery.  The Impella heart pumps are in over 1,000 U.S. hospitals and are used in 98% of the top U.S. heart hospitals, and since 2008, there have been over 750 patients in Massachusetts that have been supported by the devices.  In Massachusetts, Abiomed has added over 200 employees and will add another 100+ jobs over the next 18 months as the Company significantly expands its manufacturing capacity and global training facility in Danvers.

The Impella 2.5™, Impella CP® and Impella 5.0™ are FDA-approved as a therapy to treat severe heart attack patients in cardiogenic shock with the unique ability to enable native heart recovery, allowing patients to return home with their own heart.  The Impella 2.5 is additionally approved to treat advanced heart failure patients undergoing elective percutaneous coronary interventions (PCI) such as stenting or balloon angioplasty, to re-open blocked coronary arteries.  Abiomed’s right-side heart pump, the Impella RP®, is approved to treat patients experiencing right heart failure.

  • Dan Wolpert, 47, suffered cardiogenic shock following a severe heart attack in 2008 and received the Impella 2.5 heart pump at UMass Memorial Medical Center in Worcester, Mass. The Impella device stabilized and supported Dan through a procedure to place two stents, allowing his heart muscle to rest while performing the work for his heart. “The Impella heart pump allowed physicians to stabilize my heart and saved me from needing a heart transplant,” said Dan Wolpert.  
  • Christine Alber, 27, was suffering from cardiogenic shock and was transferred to Tufts Medical Center in Boston, Mass., where she received support from the Impella 2.5 on the left side of heart and the Impella RP on the right side of her heart, without ever undergoing heart surgery. “As a young female with no prior history of heart complications, my event was sudden and severely life threatening. Fortunately, physicians were able to support the left and right side of my heart with the help of Impella CP and Impella RP, allowing my heart the chance to rest and recover. Since then I, like many other patients treated with Impella, have returned to a normal and active lifestyle,” said Christine Alber.    
  • Howard Gaynor, 71, was at Hartford Hospital in Hartford, Conn. for a routine procedure when his heart rate spiked and his cardiac condition began rapidly deteriorating. His right coronary artery was blocked 100%. The Impella RP right side device was inserted and restored blood flow to the rest of his organs.  Despite the intense stress on both sides of his heart, Howard's left and right ventricles are both functioning normally today. “The Impella RP supported the right side of my heart when it was too weak to function on its own. This device gave my heart the time it needed to recover and, ultimately gave me a second chance at life,” said Howard Gaynor.

Clinical data recently supported by the FDA demonstrates that early stabilization with the Impella heart pumps in the setting of severe heart attacks with cardiogenic shock, improve survival in these patients. Additionally, in the setting of advanced heart failure, a Protected PCI™ procedure with Impella has the ability to improve the quality of life in patients who often have no other options to improve their heart function. 

ABOUT ABIOMED Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com .

Abiomed is a corporate sponsor of the MedTech and BioTech Veteran Program (MVP), a non-profit organization committed to networking industry, mentors and veterans for meaningful employment in the life sciences.  For more information on the program, please visit: www.mvpvets.org .

FORWARD-LOOKING STATEMENTS This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

For further information please contact:  Aimee Genzler Director, Corporate Communications 978-646-1553 agenzler@abiomed.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 291

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 82

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Three Deal Reviews Put Merger Terms Under Scrutiny

Updated Category News Views 5

Three proposed transactions just picked up the sort of legal glare boards hate seeing. A shareholder-rights firm, Halper Sadeh, said on November 18, 2026 that it is investigating whether the deals involving Greenland Energy, Rapid Micro Biosystems and Aytu BioPharma may involve federal securities-law violations or breaches of fiduciary duty. That is an allegation worth...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 131

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 107

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 96

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 135

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 253

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading
HashKey and Base Aim to Bridge Asia With Liquidity

Updated Category News Views 18

A blockchain partnership can sound like confetti until the plumbing matters. This one at least points at a real commercial choke point: Asian-originated tokenized assets need deeper pools of global onchain capital, while global networks need credible asset supply and institutional access. HashKey Group's HSK Chain and Coinbase-built Base say they intend to tackle both...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 176

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading

Top 5 Most Recently Viewed Articles

Class Action Lawsuit: CarMax Investors, Time to Act Now!

Updated Category News Views 232

Class Action Lawsuit for CarMax Investors Investors in CarMax, Inc. (NYSE: KMX) have found themselves facing a significant legal opportunity. The Rosen Law Firm, noted for its focus on protecting investor rights, has initiated a class action lawsuit that specifically addresses the concerns of securitiesholders. This lawsuit applies to purchasers of CarMax securities from...

Continue Reading
Plumbing Pitfalls: When Water Heater Noises Spell Trouble

Updated Category News Views 33

Understanding the Clamor from Your Water Heater The hustle and bustle of everyday life often drown out the less important noises. But when your water heater starts making a ruckus, maybe it's time to listen. From the keen ears of Jared Voss, a plumbing expert with his roots dug deep in Clinton, Iowa, we get the lowdown on what these noises could mean for your plumbing....

Continue Reading
Walmart Enhances Shopping Experience with Inclusive Carts

Updated Category News Views 288

Walmart Launches Caroline's Carts to Enhance Shopping Experience Today, Walmart is taking a big step toward inclusivity by introducing Caroline’s Carts in its stores across Tennessee. These specially designed shopping carts aim to assist caregivers who look after both children and adults with disabilities, making the shopping experience easier for everyone involved....

Continue Reading
Innovative Cancer Treatments by Cyncado Enhance Tumor Regression

Updated Category News Views 191

Introduction to Promising Cancer Treatment Strategies AlphaTON Capital Corp (NASDAQ: ATON) is making significant strides through its subsidiary Cyncado Therapeutics, particularly in the realm of oncology. Recently, they unveiled their latest preclinical studies focusing on the dynamic interaction between selective A2B and A2A receptor antagonists and cancer vaccines....

Continue Reading
Vertex Stock Insights: Recent Insider Trading Highlights

Updated Category News Views 42

Significant Trading Activity at Vertex Inc. Recently, it was made known that ITEM SECOND IRR TRUST FBO ANNE MARIE WESTPHAL, a 10% owner at Vertex (NASDAQ: VERX), executed a notable insider transaction. This insider sell, documented through an SEC filing, included 75,175 shares, accumulating a transaction value of approximately $3,018,885. As the market opened the...

Continue Reading